Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 37

Results For "UK"

1151 News Found

Roche’s Columvi combo doubles survival in hard-to-treat lymphoma
Clinical Trials | December 09, 2025

Roche’s Columvi combo doubles survival in hard-to-treat lymphoma

Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma


Covestro and Allmed Partner to pioneer recycling of artificial kidney filters
News | December 09, 2025

Covestro and Allmed Partner to pioneer recycling of artificial kidney filters

The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters


Groundbreaking study identifies 250 genes driving ME & long COVID
R&D | December 08, 2025

Groundbreaking study identifies 250 genes driving ME & long COVID

76 of 180 long COVID-associated genes also linked to ME


Peapod Bio teams up with Enamine to supercharge drug discovery
R&D | December 05, 2025

Peapod Bio teams up with Enamine to supercharge drug discovery

Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target


Jacobio combo delivers 71% ORR, sets stage for first SHP-2–based NSCLC therapy
Clinical Trials | December 04, 2025

Jacobio combo delivers 71% ORR, sets stage for first SHP-2–based NSCLC therapy

Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib


FDA expands nod of Eli Lilly’s Jaypirca for earlier CLL/SLL treatment
Drug Approval | December 04, 2025

FDA expands nod of Eli Lilly’s Jaypirca for earlier CLL/SLL treatment

Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor


Citius Oncology's new therapy offers new hope for cutaneous T-cell lymphoma patients
News | December 03, 2025

Citius Oncology's new therapy offers new hope for cutaneous T-cell lymphoma patients

LYMPHIR addresses a clear clinical need in a disease with limited treatment options


Biocon Biologics secures market entry date for Denosumab biosimilars in Europe, Rest of the World
News | December 03, 2025

Biocon Biologics secures market entry date for Denosumab biosimilars in Europe, Rest of the World

The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025


LANXESS unveils next-gen biosecurity solutions for Indian poultry market at Poultry Expo
News | December 01, 2025

LANXESS unveils next-gen biosecurity solutions for Indian poultry market at Poultry Expo

LANXESS Biosecurity Solutions aims to deliver “advanced disinfection and hygiene solutions to support Indian farmers in maintaining healthier and safer farm environments